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TAKASAKI eT Al.
Gonadotropin therapy can be used as a second-line therapy in women with PCOS who have CC resistance, 7, 8 but it also causes ovarian hyperstimulation syndrome (OHSS) and multiple pregnancies. To prevent these side-effects, a low-dose, step-up follicle-stimulating hormone (FSH) regimen is widely used. However, this regimen could result in long-term daily injections of FSH, up to 28-35 days in each cycle, which increases the economic, mental, and physical burden of patients with PCOS. Therefore, a therapy other than gonadotropin therapy is needed for CC-resistant patients and some modified CC treatment protocols have been developed. 9, 10 In patients with PCOS who are receiving low-dose FSH treatment, it is difficult to predict when the follicles will respond to FSH and when follicular growth will start. As a result, the long-term administration of FSH is needed. Another problem is that the response to FSH is different among treatment cycles, even in the same patient. This suggests that there is a window that follicles can respond to gonadotropin and start follicular growth and that the window appears at random times during the treatment cycles. As long-term FSH treatment can keep the serum FSH levels high, this regimen should be able to find this window, even if it appears at random times. Based on this hypothesis, alternative treatments that can maintain high serum FSH levels are also promising for the induction of follicular growth in CC-resistant patients with PCOS. Thus, this study developed a new CC treatment protocol, named "intermittent CC treatment" (ICT). It was hypothesized that maintaining high serum FSH levels by repeating the administration of CC would effectively induce follicular growth in CC-resistant patients.
This study was undertaken to investigate whether ICT is a useful treatment method for the induction of follicular growth in CC-resistant patients with PCOS.
| MATERIAL S AND ME THODS
The project was reviewed and approved by the Institutional Review
Board of Saiseikai Shimonoseki General Hospital, Shimonoseki, Japan. Informed consent was obtained from all the patients in this study. Recruited to the study were 42 infertile women with the diagnosis of PCOS, which was diagnosed according to the criteria that were proposed by the Japanese Society of Obstetrics and
Gynecology. 11 The basal levels of luteinizing hormone (LH), FSH, testosterone, estradiol, fasting insulin, and glucose were examined between day 2 and day 5 of the menstrual cycle.
F I G U R E 1 Treatment regimens with standard clomiphene citrate (CC) treatment and intermittent CC treatment (ICT). Standard CC treatment: Patients with polycystic ovary syndrome (PCOS) were given 50 mg of CC daily for 5 days, starting on the menstrual cycle day (MCD) 5. Follicular growth was checked on MCD 14. If follicular growth was not observed by the standard CC treatment, they underwent ICT. ICT: The patients who were resistant to the standard CC treatment were given 100 mg of CC daily for 5 days (MCD 5-MCD 9) of the next menstrual cycle (first CC). The follicular growth was checked on MCD 14. If follicular growth was not observed, the patients were regarded as non-responders to the first CC and were given a further 100 mg/day of CC daily for 5 days (MCD 14-MCD 18) (second CC). The follicular growth was checked on MCD 23. If follicular growth still was not observed, the patients were regarded as non-responders to the second CC and were given a further 100 mg/day of CC daily for 5 days (MCD 23-MCD 27) (third CC). If follicular growth still was not observed on MCD 32, they were regarded as non-responders to the third CC
| Intermittent clomiphene citrate treatment
The 42 When the follicles reached ≥18 mm in diameter, 10,000 IU of human chorionic gonadotropin (hCG) (Gonastropin; Asuka Pharmaceutical
Company, Ltd., Tokyo, Japan) was administered to induce ovulation.
The number of mature follicles (≥18 mm) on the day of the hCG injection was assessed. Ovulation was successfully induced from all mature follicles by the hCG injection. The baseline characteristics were compared between the responders and the non-responders of ICT.
| Statistical analyses
Statistical significance was determined by a one-way ANOVA. After the ANOVA, the Tukey-Kramer test was applied to analyze differences between groups. All the statistical analyses were performed by using SPSS for Windows v. 13.0 (SPSS, Inc., Chicago, IL, USA). The differences were considered to be significant at P < 0.05. (Table 1) .
| RE SULTS

| D ISCUSS I ON
Clomiphene citrate has been used widely as a first-line treatment for anovulatory PCOS. However, ~15%-40% of women with PCOS are resistant to the standard CC treatment. 12 The present study showed that ICT is a useful treatment method for the induction of follicular growth in patients with PCOS who are resistant to the standard CC treatment.
In general, a low-dose, step-up FSH treatment is considered as a second-line therapy for CC-resistant patients with PCOS. About 70% of women receiving low-dose FSH step-up regimens ovulate. 13 However, these women need long-term daily injections of FSH.
Gonadotropin therapy still has the potential risk of multiple pregnancies or OHSS, even if a low-dose, step-up method is applied. These results show that ICT is a much more effective method for the 100 mg CC-resistant patients than increasing the dosage of the CC.
Therefore, ICT could be tried for the 100 mg CC-resistant patients before 150 mg CC is tried. TA B L E 1 Comparison of the baseline characteristics between the responders and the non-responders randomized controlled trial will be necessary in order to evaluate the efficacy of ICT on a successful pregnancy outcome for patients with PCOS. 
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